Mitapivat

Major

Mitapivat Revumenib Revuforj Reduced revumenib exposure and reduced efficacy of revumenib or an increased risk of QT prolongation associated with the M1 metabo... Details Mitapivat Ribociclib Kisqali Increased mitapivat exposure, an increased risk of mitapivat-related adverse reactions and reduced CYP3A substrate exposure Details Mitapivat Rifabutin Mycobutin Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Rifampin Rifadin Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Rifapentine Priftin Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Rilzabrutinib Wayrilz Reduced rilzabrutinib exposure, reduced efficacy of rilzabrutinib, increased CYP3A substrate exposure and an increased risk of CYP... Details Mitapivat Ritlecitinib Litfulo Increased mitapivat exposure Details Mitapivat Ritonavir Norvir Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Ruxolitinib Jakafi Reduced CYP3A/CYP2C9 substrate exposure Details Mitapivat Salmeterol Serevent Reduced CYP3A substrate exposure Details Mitapivat Saquinavir Increased mitapivat exposure, an increased risk of mitapivat-related adverse reactions and reduced CYP3A substrate exposure Details Mitapivat Schizandra Increased mitapivat exposure Details Mitapivat Sebetralstat Reduced sebetralstat exposure and reduced efficacy of sebetralstat Details Mitapivat Segesterone Reduced hormonal contraceptive exposure Details Mitapivat Selpercatinib Retevmo Reduced selpercatinib exposure and reduced anti-tumor activity Details Mitapivat Selumetinib Koselugo Reduced selumetinib exposure and reduced efficacy of selumetinib Details Mitapivat Sevabertinib Hyrnuo Reduced sevabertinib exposure and reduced efficacy of sevabertinib Details Mitapivat Sildenafil Liqrev Reduced sildenafil exposure Details Mitapivat Simeprevir Olysio® Reduced CYP3A substrate exposure Details Mitapivat Sirolimus Felycin Increased P-gp substrate exposure; reduced CYP3A substrate exposure Details Mitapivat Sonidegib Odomzo Reduced CYP3A substrate exposure Details Mitapivat Sonrotoclax Reduced sonrotoclax exposure and reduced efficacy of sonrotoclax Details Mitapivat Sotorasib Lumakras Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Stiripentol Diacomit Increased mitapivat exposure Details Mitapivat St John's Wort Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Sufentanil Dsuvia Reduced CYP3A substrate exposure Details Mitapivat Sunitinib Sutent Reduced CYP3A substrate exposure Details Mitapivat Sunvozertinib Zegfrovy Reduced sunvozertinib exposure and reduced efficacy of sunvozertinib Details Mitapivat Suzetrigine Journavx Reduced suzetrigine and M6-SUZ exposure, reduced efficacy of suzetrigine, reduced sensitive CYP3A substrate exposure and reduced e... Details Mitapivat Tacrolimus Astagraf Increased P-gp substrate exposure; reduced CYP3A substrate exposure Details Mitapivat Taletrectinib Ibtrozi Reduced taletrectinib exposure and reduced efficacy of taletrectinib Details Mitapivat Tamoxifen Nolvadex® Reduced CYP3A substrate exposure Details Mitapivat Telaprevir Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Telithromycin Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Mitapivat Telotristat Ethyl Xermelo Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Temsirolimus Torisel Reduced CYP3A substrate exposure Details Mitapivat Terfenadine Reduced CYP3A substrate exposure Details Mitapivat Tezacaftor Reduced tezacaftor exposure and reduced efficacy of tezacaftor Details Mitapivat Thioridazine Reduced mitapivat exposure and reduced efficacy of mitapivat Details Mitapivat Ticagrelor Brilinta Reduced CYP3A substrate exposure Details